Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient

Plain-language summary

This study examined the expression levels of markers called Foxp3 and Vimentin in kidney transplant recipients. It enrolled patients over 18 who were on the waiting list and underwent transplantation. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Assistance Publique - Hôpitaux de Paris

Intervention

Renal Transplant

Start date

9/1/2010

Estimated completion

1/1/2015

Countries

France

Related genes

Locations

• Créteil, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* All renal transplant recipients aged \>18 years with informed consent
* Kidney transplantation in one of the centers participating in the study all patients registered on the waiting list to the Agency of Biomedicine
* Supported by a conventional procedure
* Informed consent signed.
* No pregnancy or lactation in progress.
* Serology HIV and (HCV negative suppressed by amendment n°2)
* No contraindication for a biopsy at 1 year post transplant

Exclusion Criteria:

* Positive crossmatch, focal segmental glomerulosclerosis (FSGS) as primary nephropathy, HIV positive population
* Absence of registration on the waiting list for transplantation with the Agency of Biomedicine
* HIV-positive serology
* Chronic renal failure secondary to focal segmental hyalinosis
* Cross-match historical or cross match of the day positive T or B awareness
* Patient included in a Memorandum of industry (suppressed by amendment n°1)
* No affiliation to a social security scheme
* Patients with early failure due to immediate complications (4%) will be included but will not be considered for analysis